We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Wearable Lab on the Skin Simultaneously Monitors Glucose, Alcohol and Lactate in Real-Time

By LabMedica International staff writers
Posted on 10 May 2022
Print article
Image: The device can be worn on the upper arm while the wearer goes about their day (Photo courtesy of UC San Diego)
Image: The device can be worn on the upper arm while the wearer goes about their day (Photo courtesy of UC San Diego)

Most commercial health monitors, such as continuous glucose monitors for patients with diabetes, only measure one signal, thereby leaving out information that could help people with diabetes, for example, manage their disease more effectively. Monitoring alcohol levels is useful because drinking alcohol can lower glucose levels. Knowing both levels can help people with diabetes prevent their blood sugar from dropping too low after having a drink. Combining information about lactate, which can be monitored during exercise as a biomarker for muscle fatigue, is also useful because physical activity influences the body’s ability to regulate glucose. Now, engineers have developed a prototype of a wearable that can continuously monitor several health stats - glucose, alcohol, and lactate levels - simultaneously in real-time.

The device developed by researchers at UC San Diego (La Jolla, CA, USA) is about the size of a stack of six quarters. It is applied to the skin through a Velcro-like patch of microscopic needles, or microneedles, that are each about one-fifth the width of a human hair. Wearing the device is not painful - the microneedles barely penetrate the surface of the skin to sense biomolecules in interstitial fluid, which is the fluid surrounding the cells beneath the skin. Different enzymes on the tips of the microneedles react with glucose, alcohol and lactate in interstitial fluid. These reactions generate small electric currents, which are analyzed by electronic sensors and communicated wirelessly to an app developed by the researchers. The results are displayed in real time on a smartphone.

An advantage of using microneedles is that they directly sample the interstitial fluid, and research has shown that biochemical levels measured in that fluid correlate well with levels in blood. The microneedle patch, which is disposable, can be detached from the electronic case for easy replacement. The electronic case, which is reusable, houses the battery, electronic sensors, wireless transmitter and other electronic components. The device can be recharged on any wireless charging pad used for phones and smartwatches. Integrating all these components together into one small, wireless wearable was one of the team’s biggest challenges. It also required some clever design and engineering to combine the reusable electronics, which must stay dry, with the microneedle patch, which gets exposed to biological fluid.

The wearable was tested on five volunteers, who wore the device on their upper arm, while exercising, eating a meal, and drinking a glass of wine. The device was used to continuously monitor the volunteers’ glucose levels simultaneously with either their alcohol or lactate levels. The glucose, alcohol and lactate measurements taken by the device closely matched the measurements taken respectively by a commercial blood glucose monitor, Breathalyzer, and blood lactate measurements performed in the lab. The researchers plan to further develop the technology for commercialization. Next steps include testing and improving upon how long the microneedle patch can last before being replaced. The researchers are also excited about the possibility of adding more sensors to the device to monitor medication levels in patients and other health signals.

“This is like a complete lab on the skin,” said center director Joseph Wang, a professor of nanoengineering at UC San Diego. “It is capable of continuously measuring multiple biomarkers at the same time, allowing users to monitor their health and wellness as they perform their daily activities.”

“With our wearable, people can see the interplay between their glucose spikes or dips with their diet, exercise and drinking of alcoholic beverages. That could add to their quality of life as well,” said Farshad Tehrani, a nanoengineering Ph.D. student in Wang’s lab and one of the co-first authors of the study.

“We’re starting at a really good place with this technology in terms of clinical validity and relevance,” said Patrick Mercier, a professor of electrical and computer engineering at UC San Diego. “That lowers the barriers to clinical translation. The beauty of this is that it is a fully integrated system that someone can wear without being tethered to benchtop equipment.”

Related Links:
UC San Diego 

Gold Supplier
Quantitative Immunoassay Analyzer
FIA8000
New
TSI Stimulating Assay
Thyretain TSI Stimulating Reporter BioAssay
New
Rapid Procalcitonin (PCT) Test
AQT90 FLEX PCT Assay
New
Whole Blood Control
ESR-Chex Plus

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.